Relaxin stimulates multiple signaling pathways: Activation of cAMP, PI3K, and PKCζ in THP-1 cells

Annals of the New York Academy of Sciences

Volumn 1041, Issue , 2005, Pages 272-279

  Dessauer, Carmen W ^a   Nguyen, Bao T ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adenylyl cyclase; Cyclic AMP; PI3K; PKC zeta; Relaxin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENYLATE CYCLASE; CYCLIC AMP; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE C ZETA; RELAXIN; VASCULOTROPIN;

ANIMAL CELL; CELL STRAIN MCF 7; CONFERENCE PAPER; ENZYME ACTIVATION; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MESANGIUM CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 23644433831     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1282.040     Document Type: Conference Paper

References (41)

1. BRADDON, S.A. 1978. Relaxin-dependent adenosine 6′,5′- monophosphate concentration changes in the mouse pubic symphysis. Endocrinology 102: 1292-1299.
2. SANBORN, B.M., N.W. WEISBRODT, H.S. KUO & O.D. SHERWOOD. 1980. The interaction of relaxin with the rat uterus. 1. Effect of cyclic nucleotide levels and spontaneous contractile activity. Endocrinology 106: 1210-1215.
3. CHEAH, S.H. & O.D. SHERWOOD. 1980. Target tissues for relaxin in the rat: tissue distribution of injected 1251-labeled relaxin and tissue changes in adenosine 3′,5′-monophosphate levels after in vitro relaxin incubation. Endocrinology 106: 1203-1209.
4. SANBORN, B.M. & O.D. SHERWOOD. 1981. Effect of relaxin on bound cAMP in rat uterus. Endocrinol. Res. Commun. 8: 179-192.
5. HSU, C.J., S.M. MCCORMACK & B.M. SANBORN. 1985. The effect of relaxin on cyclic AMP concentrations in rat myometrial cells in culture. Endocrinology 116: 2029-2035.
6. SHERWOOD, O.D. 1994. Relaxin. In The Physiology of Pregnancy. E. Knobil & J.D. Neill, Eds.: 861-1009. Raven Press Ltd. New York.
7. SANBORN, B.M., H.S. KUO, N.W. WEISBRODT & O.D. SHERWOOD. 1982. Effect of porcine relaxin on cyclic nucleotide levels and spontaneous contractions of the rat uterus. In Relaxin. R.R. Anderson, Ed.: 273-287. Plenum Press. New York.
8. SANBORN, B.M., K. ANWER, M. MONGA, et al. 1995. Mechanisms controlling the acute effects of relaxin on the myometrium. In Progress in Relaxin Research. A.H. MacLennan, G.W. Traegear & G.D. Bryant-Greenwood, Eds.: 289-297. Global Publication Services. Sinapore.
9. SANBORN, B.M., K. DODGE, C.Y. KU & C. YUE. 2001. Relaxin and scaffolding proteins in signalling crosstalk. In Relaxin 2000. G.W. Tragaer, R. Ivell, R.A. Bathgate & J.D. Wade, Eds.: 279-283. Kluwer Academic Publishers. Dordrecht, The Netherlands.
10. FEI, D.T., M.C. GROSS, J.L. LOFGREN, et al. 1990. Cyclic AMP response to recombinant human relaxin by cultured human endometrial cells-a specific and high throughput in vitro bioassay. Biochem. Biophys. Res. Commun. 170: 214-222.
11. PARSELL, D.A., J.Y. MAK, E.P. AMENTO & E.N. UNEMORI. 1996. Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1. J. Biol. Chem. 271: 27936-27941.
12. TELGMANN, R., E. MARONDE, K. TASKEN & B. GELLERSEN. 1997. Activated protein kinase A is required for differentiation-dependent transcription of the decidual prolactin gene in human endometrial stromal cells. Endocrinology 138: 929-937.
13. NGUYEN, B.T., L. YANG, B.M. SANBORN & C.W. DESSAUER. 2003. Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3′,5′-monophosphate by relaxin. Mol. Endocrinol. 17: 1075-1084.
14. HSU, S.Y., K. NAKABAYASHI, S. NISHI, et al. 2002. Activation of orphan receptors by the hormone relaxin. Science 295: 671-674.
15. BARBER, R. 1986. Discrimination between intact cell desensitization and agonist affinity changes. Mol. Cell Endocrinol. 46: 263-270.
16. BHALLA, R.C., R.M. SANBORN & S.G. KORENMAN. 1972. Hormonal interactions in the uterus: inhibition of isoproterenol-induced accumulation of adenosine 3′:5′-cyclic monophosphate by oxytocin and prostaglandins. Proc. Natl. Acad. Sci. USA 69: 3761-3764.
17. WYMANN, M.P. & L. PIROLA. 1998. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta 1436: 127-150.
18. CANTLEY, L.C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
19. YART, A., S. ROCHE, R. WETZKER, et al. 2002. A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J. Biol. Chem. 277: 21167-21178.
20. CURNOCK, A.P., M.K. LOGAN & S.G. WARD. 2002. Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 105: 125-136.
21. COLOMBO, F., J. NOEL, P. MAYERS, et al. 2001. beta-Adrenergic stimulation of rat cardiac fibroblasts promotes protein synthesis via the activation of phosphatidylinositol 3-kinase. J. Mol. Cell Cardiol. 33: 1091-1106.
22. KAWABE, J., G. IWAMI, T. EBINA, et al. 1994. Differential activation of adenylyl cyclase by protein kinase C isoenzymes. J. Biol. Chem. 269: 16554-16558.
23. NGUYEN, B.T. & C.W. DESSAUER. 2005. Relaxin stimulates protein kinase C zeta translocation: requirement for cyclic adenosine 3′,5′- monophosphate production. Mol. Endocrinol. 19. In press.
24. MONGA, M., C.Y. KU, K. DODGE & B.M. SANBORN. 1996. Oxytocin-stimulated responses in a pregnant human immortalized myometrial cell line. Biol. Reprod. 55: 427-432.
25. WOLF, G., U. HABERSTROH & E.G. NEILSON. 1992. Angiotensin 11 stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am. J. Pathol. 140: 95-107.
26. BARTSCH, O., B. BARTLICK & R. IVELL. 2001. Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity. Mol. Hum. Reprod. 7: 799-809.
27. UNEMORI, E.N., M. LEWIS, J. CONSTANT, et al. 2000. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound. Repair Regen. 8: 361-370.
28. SACCHI, T.B., D. BANI, M.L. BRANDI, et al. 1994. Relaxin influences growth, differentiation and cell-cell adhesion of human breast-cancer cells in culture. Int. J. Cancer 57: 129-134.
29. MCDONALD, G.A., P. SARKAR, H. RENNKE, et al. 2003. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal flbrosis in vivo. Am. J. Physiol. 285: F59-F67.
30. ZHANG, Q., S.H. LIU, M. ERIKSON, et al. 2002. Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J. Cell Biochem. 85: 536-544.
31. DSCHIETZIG, T., C. BARTSCH, C. RICHTER, et al. 2003. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ. Res. 92: 32-40.
32. UNEMORI, E.N., M.E. ERIKSON, S.E. ROCCO, et al. 1999. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum. Reprod. 14: 800-806.
33. PALEJWALA, S., D.E. STEIN, G. WEISS, et al. 2001. Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. Endocrinology 142: 3405-3413.
34. LENHART, J.A., P.L. RYAN, K.M. OHLETH, et al. 2001. Relaxin increases secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 during uterine and cervical growth and remodeling in the pig. Endocrinology 142: 3941-3949.
35. BINDER, C., T. HAGEMANN, B. HUSEN, et al. 2002. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol. Hum. Reprod. 8: 789-796.
36. HUSSAIN, S., J.W. ASSENDER, M. BOND, et al. 2002. Activation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J. Biol. Chem. 277: 27345-27352.
37. PAL, S., K. DATTA, R. KHOSRAVI-FAR & D. MUKHOPADHYAY. 2001. Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 276: 2395-2403.
38. MILANINI-MONGIAT, J., J. POUYSSEGUR & G. PAGES. 2002. Identification of two p42/p44 mitogen activated kinases phosphorylation sites on Sp1: Their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277: 20631-20639.
39. JUNG, Y.D., W. LIU, N. REINMUTH, et al. 2001. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 4: 155-162.
40. ALPER, O., E.S. BERGMANN-LEITNER, S. ABRAMS & Y.S. CHO-CHUNG. 2001. Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase A downregulation and cytoplasmic export of CRE-binding proteins. Mol. Cell. Biochem. 218: 55-63.
41. PRICE, D.J., S. AVRAHAM, J. FEUERSTEIN, et al. 2002. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1,2 pathways. Cell Commun. Adhes. 9: 87-102.